Fangjiomics: In Search of Effective and Safe Combination Therapies
Identifieur interne : 000757 ( Istex/Corpus ); précédent : 000756; suivant : 000758Fangjiomics: In Search of Effective and Safe Combination Therapies
Auteurs : Wang ; Liu ; Cheng ; WangSource :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2011-08.
English descriptors
- KwdEn :
Abstract
Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.
Url:
DOI: 10.1177/0091270010382913
Links to Exploration step
ISTEX:0EA0943A6E0184924442A5D829ECE55B19373453Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fangjiomics: In Search of Effective and Safe Combination Therapies</title><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name><affiliation><mods:affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu" sort="Liu" uniqKey="Liu" last="Liu">Liu</name><affiliation><mods:affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Cheng" sort="Cheng" uniqKey="Cheng" last="Cheng">Cheng</name><affiliation><mods:affiliation>Pharmaceutical Research Institute, Zhejiang University, China</mods:affiliation></affiliation></author><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name><affiliation><mods:affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0EA0943A6E0184924442A5D829ECE55B19373453</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1177/0091270010382913</idno><idno type="url">https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000757</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Fangjiomics: In Search of Effective and Safe Combination Therapies</title><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name><affiliation><mods:affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu" sort="Liu" uniqKey="Liu" last="Liu">Liu</name><affiliation><mods:affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Cheng" sort="Cheng" uniqKey="Cheng" last="Cheng">Cheng</name><affiliation><mods:affiliation>Pharmaceutical Research Institute, Zhejiang University, China</mods:affiliation></affiliation></author><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name><affiliation><mods:affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Clinical Pharmacology</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-08">2011-08</date><biblScope unit="volume">51</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1132">1132</biblScope><biblScope unit="page" to="1151">1151</biblScope></imprint><idno type="ISSN">0091-2700</idno></series><idno type="istex">0EA0943A6E0184924442A5D829ECE55B19373453</idno><idno type="DOI">10.1177/0091270010382913</idno><idno type="ArticleID">JCPH5434</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Fangjiomics</term><term>array design</term><term>combination therapy</term><term>multicomponent therapeutic</term><term>pathways spectrum</term><term>target therapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr Wang PhD</name><affiliations><json:string>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</json:string></affiliations></json:item><json:item><name>Dr Liu PhD</name><affiliations><json:string>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</json:string></affiliations></json:item><json:item><name>Dr Cheng PhD</name><affiliations><json:string>Pharmaceutical Research Institute, Zhejiang University, China</json:string></affiliations></json:item><json:item><name>Mr Wang</name><affiliations><json:string>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Fangjiomics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>combination therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>array design</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>target therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pathways spectrum</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multicomponent therapeutic</value></json:item></subject><articleId><json:string>JCPH5434</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.</abstract><qualityIndicators><score>8.416</score><pdfVersion>1.7</pdfVersion><pdfPageSize>585 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>855</abstractCharCount><pdfWordCount>8377</pdfWordCount><pdfCharCount>61645</pdfCharCount><pdfPageCount>20</pdfPageCount><abstractWordCount>118</abstractWordCount></qualityIndicators><title>Fangjiomics: In Search of Effective and Safe Combination Therapies</title><genre><json:string>review-article</json:string></genre><host><volume>51</volume><publisherId><json:string>JCPH</json:string></publisherId><pages><total>20</total><last>1151</last><first>1132</first></pages><issn><json:string>0091-2700</json:string></issn><issue>8</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1552-4604</json:string></eissn><title>The Journal of Clinical Pharmacology</title><doi><json:string>10.1002/(ISSN)1552-4604</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1177/0091270010382913</json:string></doi><id>0EA0943A6E0184924442A5D829ECE55B19373453</id><score>0.078923956</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Fangjiomics: In Search of Effective and Safe Combination Therapies</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>2011 American College of Clinical Pharmacology</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Fangjiomics: In Search of Effective and Safe Combination Therapies</title><author xml:id="author-1"><persName><surname>Wang</surname></persName><roleName type="degree">Dr</roleName><note type="correspondence"><p>Correspondence: Address for correspondence: Zhong Wang, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, 18 Baixincang, Dongzhimennei, Beijing 100700, China; e‐mail: .</p></note><affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</affiliation></author><author xml:id="author-2"><persName><surname>Liu</surname></persName><roleName type="degree">Dr</roleName><affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</affiliation></author><author xml:id="author-3"><persName><surname>Cheng</surname></persName><roleName type="degree">Dr</roleName><affiliation>Pharmaceutical Research Institute, Zhejiang University, China</affiliation></author><author xml:id="author-4"><persName><surname>Wang</surname></persName><roleName type="degree">Mr</roleName><affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</affiliation></author></analytic><monogr><title level="j">The Journal of Clinical Pharmacology</title><idno type="pISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><idno type="DOI">10.1002/(ISSN)1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-08"></date><biblScope unit="volume">51</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1132">1132</biblScope><biblScope unit="page" to="1151">1151</biblScope></imprint></monogr><idno type="istex">0EA0943A6E0184924442A5D829ECE55B19373453</idno><idno type="DOI">10.1177/0091270010382913</idno><idno type="ArticleID">JCPH5434</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Fangjiomics</term></item><item><term>combination therapy</term></item><item><term>array design</term></item><item><term>target therapy</term></item><item><term>pathways spectrum</term></item><item><term>multicomponent therapeutic</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1002/(ISSN)1552-4604</doi><issn type="print">0091-2700</issn><issn type="electronic">1552-4604</issn><idGroup><id type="product" value="JCPH"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JOURNAL OF CLINICAL PHARMACOLOGY">The Journal of Clinical Pharmacology</title></titleGroup></publicationMeta><publicationMeta level="part" position="08108"><doi origin="wiley">10.1002/jcph.2011.51.issue-8</doi><numberingGroup><numbering type="journalVolume" number="51">51</numbering><numbering type="journalIssue" number="8">8</numbering></numberingGroup><coverDate startDate="2011-08">August 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="1" status="forIssue"><doi origin="wiley">10.1177/0091270010382913</doi><idGroup><id type="unit" value="JCPH5434"></id></idGroup><countGroup><count type="pageTotal" number="20"></count></countGroup><titleGroup><title type="tocHeading1">Review</title></titleGroup><copyright>2011 American College of Clinical Pharmacology</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:3.2.0 mode:FullText" date="2013-03-07"></event><event type="firstOnline" date="2013-03-07"></event><event type="publishedOnlineFinalForm" date="2013-03-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-30"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1132">1132</numbering><numbering type="pageLast" number="1151">1151</numbering></numberingGroup><correspondenceTo> Address for correspondence: Zhong Wang, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, 18 Baixincang, Dongzhimennei, Beijing 100700, China; e‐mail: <email>zhonw@vip.sina.com</email>.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JCPH.JCPH5434.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="100"></count><count type="linksCrossRef" number="131"></count><count type="figureTotal" number="5"></count><count type="tableTotal" number="2"></count><count type="formulaTotal" number="0"></count></countGroup><titleGroup><title type="main">Fangjiomics: In Search of Effective and Safe Combination Therapies</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><honorifics>Dr</honorifics><givenNames>Zhong</givenNames><familyName>Wang</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><honorifics>Dr</honorifics><givenNames>Jun</givenNames><familyName>Liu</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><honorifics>Dr</honorifics><givenNames>Yiyu</givenNames><familyName>Cheng</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><honorifics>Mr</honorifics><givenNames>Yongyan</givenNames><familyName>Wang</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="CN"><unparsedAffiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="CN"><unparsedAffiliation>Pharmaceutical Research Institute, Zhejiang University, China</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Fangjiomics</keyword><keyword xml:id="k2">combination therapy</keyword><keyword xml:id="k3">array design</keyword><keyword xml:id="k4">target therapy</keyword><keyword xml:id="k5">pathways spectrum</keyword><keyword xml:id="k6">multicomponent therapeutic</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. <i>Fangjiomics</i> is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Fangjiomics: In Search of Effective and Safe Combination Therapies</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Fangjiomics: In Search of Effective and Safe Combination Therapies</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Wang</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</affiliation><description>Correspondence: Address for correspondence: Zhong Wang, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, 18 Baixincang, Dongzhimennei, Beijing 100700, China; e‐mail: .</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Liu</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Cheng</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Pharmaceutical Research Institute, Zhejiang University, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Mr</namePart><namePart type="family">Wang</namePart><affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2011-08</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="tables">2</extent><extent unit="references">100</extent></physicalDescription><abstract lang="en">Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.</abstract><subject lang="en"><genre>keywords</genre><topic>Fangjiomics</topic><topic>combination therapy</topic><topic>array design</topic><topic>target therapy</topic><topic>pathways spectrum</topic><topic>multicomponent therapeutic</topic></subject><relatedItem type="host"><titleInfo><title>The Journal of Clinical Pharmacology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0091-2700</identifier><identifier type="eISSN">1552-4604</identifier><identifier type="DOI">10.1002/(ISSN)1552-4604</identifier><identifier type="PublisherID">JCPH</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1132</start><end>1151</end><total>20</total></extent></part></relatedItem><identifier type="istex">0EA0943A6E0184924442A5D829ECE55B19373453</identifier><identifier type="DOI">10.1177/0091270010382913</identifier><identifier type="ArticleID">JCPH5434</identifier><accessCondition type="use and reproduction" contentType="copyright">2011 American College of Clinical Pharmacology</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><enrichments><json:item><type>multicat</type><uri>https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/enrichments/multicat</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/CyberinfraV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000757 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000757 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= CyberinfraV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0EA0943A6E0184924442A5D829ECE55B19373453
|texte= Fangjiomics: In Search of Effective and Safe Combination Therapies
}}
| This area was generated with Dilib version V0.6.25. |  |